LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. märts 2026, 18:13 UTC

Omandamised, ülevõtmised, äriostud

Shell to Sell Jiffy Lube to Monomoy in $1.3 Billion Deal -- Update

9. märts 2026, 17:20 UTC

Uudisväärsed sündmused

U.S. Ag Industry Calls for Government Intervention on Fertilizer Prices

9. märts 2026, 17:15 UTC

Omandamised, ülevõtmised, äriostud

Shell to Sell Jiffy Lube and Premium Velocity to Monomoy for $1.3 Billion

9. märts 2026, 23:52 UTC

Market Talk

Gold Steady; May Be Supported by Dollar's Weakness -- Market Talk

9. märts 2026, 23:50 UTC

Market Talk

Nikkei May Rise as Fears About Higher Energy Prices Ease -- Market Talk

9. märts 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9. märts 2026, 23:46 UTC

Market Talk

Uudisväärsed sündmused

Correction to Crude Prices Market Talk on March 9

9. märts 2026, 23:42 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Fall Amid Developments That Could Help Supply -- Market Talk

9. märts 2026, 23:08 UTC

Uudisväärsed sündmused

Front-Month WTI Futures Drop 7.9% to $87.29/bbl, ICE Data Show

9. märts 2026, 23:07 UTC

Uudisväärsed sündmused

Front-Month WTI Futures Fall After Trump Says Iran War Will Be Over 'Very Soon'

9. märts 2026, 21:29 UTC

Omandamised, ülevõtmised, äriostud

Fortescue Now Fully Owns Peru's Canariaco Copper Project

9. märts 2026, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Fortescue Completes Acquisition of Remaining Alta Copper Shares

9. märts 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. märts 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9. märts 2026, 20:47 UTC

Uudisväärsed sündmused

The 24 Hours When Oil Markets Went Wild -- WSJ

9. märts 2026, 20:33 UTC

Uudisväärsed sündmused

Stock Market Today: Oil Slips, Stocks Bounce on Trump War-Progress Comments Headline -- WSJ

9. märts 2026, 20:14 UTC

Market Talk

Uudisväärsed sündmused

Oil Moves Lower As Trump Says War Could End Soon -- Market Talk

9. märts 2026, 19:33 UTC

Uudisväärsed sündmused

High Oil Prices Could Crimp Convenience Store Margins -- Barrons.com

9. märts 2026, 19:17 UTC

Market Talk

Uudisväärsed sündmused

Prospect of Added Supply From Oil Reserves Ease Inflation Fears -- Market Talk

9. märts 2026, 19:14 UTC

Market Talk

Oil Settles Off Highs As G7 Discusses Tapping Reserves -- Market Talk

9. märts 2026, 19:00 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

9. märts 2026, 18:23 UTC

Market Talk

Uudisväärsed sündmused

BofA Drops Canada Rate-Cut Call on Higher Oil Prices -- Market Talk

9. märts 2026, 17:58 UTC

Omandamised, ülevõtmised, äriostud

Shell to Sell Jiffy Lube to Monomoy in $1.3B Deal -- Update

9. märts 2026, 17:57 UTC

Omandamised, ülevõtmised, äriostud

Activist Investors Target Food Companies as Growth Slows. Lamb Weston Is the Latest. -- Barrons.com

9. märts 2026, 17:41 UTC

Uudisväärsed sündmused

U.S. and Western Allies Turn to Reserves to Counteract Gulf Oil Crisis -- WSJ

9. märts 2026, 17:41 UTC

Market Talk

Uudisväärsed sündmused

Reports of Saudi Production Shut-Ins Keep Bid in Crude -- Market Talk

9. märts 2026, 17:08 UTC

Market Talk

Canada Rate Outlook Shifts From Long Pause to Late 2026 Hike -- Market Talk

9. märts 2026, 17:04 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

9. märts 2026, 17:04 UTC

Market Talk

Uudisväärsed sündmused

Treasury Yields, Dollar Off Highs as G7 Tackles Oil Shock -- Market Talk

9. märts 2026, 17:00 UTC

Omandamised, ülevõtmised, äriostud

Shell to Sell Jiffy Lube and Premium Velocity to Monomoy for $1.3B

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.